BACKGROUND/AIMS: The urokinase pathway of plasminogen activation is known to be involved in proteolytic degradation of the extracellular matrix during carcinoma invasion. METHODOLOGY: We immunohistochemically examined 97 colorectal carcinomas for the expression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) to investigate whether uPA and PAI-1 expressions could serve as prognostic parameters; the gene expression of uPA and PAI-1 in human colon cancer tissues was also analyzed using reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: The relative expression levels of uPA and PAI-1 mRNAs were well correlated with immunoreactivities of uPA and PAI-1, respectively (p < 0.05). In immunohistochemical staining, diffuse specific staining was observed in the cytoplasm of carcinoma cells. uPA expression was detected in 57 carcinoma specimens (58.8%) and PAI-1 expression was detected in 36 specimens (37.1%). With regard to 5-year overall survival rate, patients whose tumors had positive uPA and negative PAI-1 immunoreactivities had a significantly poorer prognosis (p < 0.05). In multivariate analysis, the combined variable of uPA and PAI-1 was shown to be an independent prognostic indicator. CONCLUSIONS: Our results suggest that immunohistochemical combined analysis of uPA and PAI-1 may be a useful prognostic factor in colorectal carcinoma patients.
BACKGROUND/AIMS: The urokinase pathway of plasminogen activation is known to be involved in proteolytic degradation of the extracellular matrix during carcinoma invasion. METHODOLOGY: We immunohistochemically examined 97 colorectal carcinomas for the expression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) to investigate whether uPA and PAI-1 expressions could serve as prognostic parameters; the gene expression of uPA and PAI-1 in humancolon cancer tissues was also analyzed using reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: The relative expression levels of uPA and PAI-1 mRNAs were well correlated with immunoreactivities of uPA and PAI-1, respectively (p < 0.05). In immunohistochemical staining, diffuse specific staining was observed in the cytoplasm of carcinoma cells. uPA expression was detected in 57 carcinoma specimens (58.8%) and PAI-1 expression was detected in 36 specimens (37.1%). With regard to 5-year overall survival rate, patients whose tumors had positive uPA and negative PAI-1 immunoreactivities had a significantly poorer prognosis (p < 0.05). In multivariate analysis, the combined variable of uPA and PAI-1 was shown to be an independent prognostic indicator. CONCLUSIONS: Our results suggest that immunohistochemical combined analysis of uPA and PAI-1 may be a useful prognostic factor in colorectal carcinomapatients.
Authors: A C Keates; S Tummala; R M Peek; E Csizmadia; B Kunzli; K Becker; P Correa; J Romero-Gallo; M B Piazuelo; S Sheth; C P Kelly; S C Robson; S Keates Journal: Infect Immun Date: 2008-06-02 Impact factor: 3.441
Authors: Petra Krause; Nina S Bobisch; Paul Thelen; Karola Koehler; Sarah Koenig; Heinz Becker; Ingo Leister Journal: Int J Colorectal Dis Date: 2010-10-08 Impact factor: 2.571
Authors: Mayara Mota de Oliveira; Gabriela Tonini Peterle; Cinthia Vidal Monteiro da Silva Couto; Lucas de Lima Maia; Andre Kühl; Joaquim Gasparini Dos Santos; Raquel Ajub Moysés; Leonardo Oliveira Trivilin; Aline Ribeiro Borçoi; Anderson Barros Archanjo; Arícia Leone Evangelista Monteiro de Assis; Fábio Daumas Nunes; Marcelo Dos Santos; Adriana Madeira Álvares da Silva Journal: Ann Med Surg (Lond) Date: 2021-04-15
Authors: Bruno Märkl; Jochen Hardt; Simon Franz; Tina Schaller; Gerhard Schenkirsch; Bernadette Kriening; Reinhard Hoffmann; Stefan Rüth Journal: Gastroenterol Res Pract Date: 2017-02-12 Impact factor: 2.260